韦里西瓜特在子心房动模型中减少了电气和结构改造
Qi Lou1, Luyifei Li1, Guangzhong Liu2
1Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
概括
在动物和细胞模型中,Vericiguat治疗改善了与心房 (AF) 相关的结构和电力重塑. 这表明,发射器被关闭了.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 前庭动 (AF) 涉及复杂的电气和结构改造.
- 已知影响心力衰竭中的心脏重塑的药物 vericiguat 在AF的治疗潜力仍然未被探索.
研究的目的:
- 为了调查 vericiguat对AF中心房结构和电力改造的影响.
- 在AF模型中阐明 vericiguat作用的基本机制.
主要方法:
- 使用快速心房节奏 (RAP) 的子模型和接受快速节奏的HL-1细胞培养物.
- 给药的 vericiguat (每天1.5毫克/公斤) 来评估其对电生理学,心声学,组织学和分子标记物的影响.
- 测量参数包括Ca2+水平,ICaL密度,TRPC6,CaN,NFAT4,Cav1.2,原蛋白I/III和ST2表达.
主要成果:
- 在动物和细胞模型中,维里西瓜特治疗显著恢复了改变的蛋白质表达,生化指数,Ca2+度和ICaL密度.
- 韦里西瓜特逆转了心房扩大,减少了心肌纤维化,防止了心房有效耐火期 (AERP) 的减少,并降低了AF诱导率.
- 涉及TRPC6,CaN,NFAT4和Cav1.2的关键分子通路被 vericiguat调节.
结论:
- 韦里西瓜特有效地改善了与心房相关的结构和电力改造.
- 这些发现凸显了 vericiguat作为治疗AF的治疗剂的潜力.
- 这项研究提供了机理性洞察力,了解在AF的背景下, vericiguat的心脏保护作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
49
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
49
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
885
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
885
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
01:28Mechanism of Cardiac Arrhythmias
965
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
965
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
778
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
778